Bone marrow failure (BMF) is a rare condition characterized by decreased production of one or more major blood cell lines, including red blood cells, granulocytes, and platelets. This leads to a reduction or absence of hematopoietic precursors in the bone marrow and supporting cells.
1. What is Bone Marrow Failure?
1.1 Definition
Bone marrow is responsible for producing blood cells such as red blood cells (which carry oxygen), white blood cells (which protect against infection), and platelets (which aid in blood clotting).
Bone marrow failure, also known as aplastic anemia, results from decreased production of one or more blood cell lines, causing a deficiency in blood cells in the peripheral blood.
The global incidence is approximately 2–5 cases per million people annually, with the highest incidence among those aged 15–25, followed by 65–69. The disease affects males and females equally. In Vietnam, bone marrow failure ranks third among hematologic diseases.
1.2 Classification
Bone marrow failure can be divided into two types:
Inherited BMF (IBMF): Including Fanconi anemia, Dyskeratosis Congenita, Shwachman-Diamond syndrome, Congenital amegakaryocytic thrombocytopenia, Blackfan-Diamond anemia, and Reticular dysgenesis.
- Acquired BMF:
- Approximately 70% of cases are idiopathic.
- Associated with medications such as anti-inflammatory drugs,
- analgesics, antihypertensives, antiarrhythmics, antithyroid
- drugs, and antibiotics like chloramphenicol.
- Exposure to chemicals such as chlorinated hydrocarbons, organophosphates, and benzene.
- Viral infections including Epstein-Barr virus, Parvovirus, HIV.
- Autoimmune diseases like rheumatoid arthritis, systemic lupus erythematosus, and autoimmune thyroid disease.
- Pregnancy.
- Paroxysmal nocturnal hemoglobinuria.
2. Diagnosis
2.1 Clinical Symptoms
Symptoms depend on which blood cell lines are affected and disease severity:
- Anemia (low red blood cells): pallor, fatigue, dyspnea.
- Leukopenia (low white blood cells): fever, chills, sore throat, recurrent or persistent infections.
- Thrombocytopenia (low platelets): petechiae, heavy menstrual bleeding, mucosal bleeding, lymphadenopathy, hepatosplenomegaly.
- Inherited forms may be associated with physical abnormalities such as short stature, bone defects, skin pigmentation anomalies, and nail or organ abnormalities.
2.2 Laboratory Tests
- Complete blood count: reduction in one or more blood cell lines; time of onset for reduction can differ for each line
- Normocytic, normochromic anemia;
low reticulocyte count disproportionate to anemia severity. - Elevated levels of hematopoietic growth factors such as thrombopoietin, erythropoietin, and granulocyte colony-stimulating factor.
- Increased serum iron with prolonged clearance.
- Bone marrow aspiration and biopsy: hypocellular marrow with fatty replacement, reduced hematopoietic cells.
- Cytogenetic analysis.
- MRI can help distinguish between marrow fat and hematopoietic tissue.
3. Can Bone Marrow Failure be Treated?
Bone marrow failure is a serious and complex condition requiring a combination of treatments.
3.1 Treatment of underlying causes
- Avoid exposure to radiation, chemicals.
- Discontinue causative medications.
3.2 Symptomatic Treatment
Anemia:
- Red blood cell transfusions
- If multiple transfusions are required, monitoring for iron overload is necessary;
- Avoid transfusions in transplant candidates.
- Platelet transfusion from platelet donated by family members is possible in patients not waiting for a transplant
Infections:
- Isolation, with appropriate protocol for preventing infection
- Limit intake of fruits and raw vegetables
- Empiric broad-spectrum antibiotics if fever is present
- Antifungal therapy if fever persists and cultures are negative.
Bleeding:
- Platelet transfusions if bleeding occurs
- High-dose immunoglobulin if platelet antibodies are present.
3.3 Specific Treatments
- Bone marrow and hematopoietic stem cell transplantation.
- Immunosuppressive therapy including corticosteroids, antithymocyte globulin (ATG), antilymphocyte globulin (ALG), cyclosporine (CsA).
- High-dose cyclophosphamide, androgens, cytokines, splenectomy in selected cases.
4. Survival in Bone Marrow Failure
Survival depends largely on disease severity and treatment. Before immunosuppressive therapy or transplantation:
- Over 25% of patients die within 4 months.
- About 50% die within 1 year.
After immunosuppressive therapy or transplantation:
- 10-year survival rates: 83% (under 20 years old), 73% (20–30 years), 68% (30–50 years), 51% (over 50 years).
- Fanconi anemia: 85% 3-year survival with sibling donor transplant; 50% with unrelated donor.
- Blackfan-Diamond anemia: 100% 40-year survival if steroid-responsive; 75% if maintained on steroids; 80% 3-year survival with sibling donor transplant; 20–30% with unrelated donor.
- Combination therapy with ATG and cyclosporine improves outcomes in over 70% of patients.
Bone marrow failure is a serious hematologic condition that can lead to life-threatening complications. Patients with genetic risk factors or exposure to toxic agents should seek medical advice promptly for early diagnosis and treatment to reduce complications.
To arrange an appointment, please call HOTLINE or make your reservation directly HERE. You may also download the MyVinmec app to schedule appointments faster and manage your reservations more conveniently.
